

# Heart rate response during exercise predicts exercise tolerance in adults with transposition of the great arteries and atrial switch operation

Xavier Iriart, Soazig Le Quellenec, Xavier Pillois, Jérémy Jaussaud, Zakaria Jalal, François Roubertie, Hervé Douard, Hubert Cochet, Jean-Benoît

Thambo

# ► To cite this version:

Xavier Iriart, Soazig Le Quellenec, Xavier Pillois, Jérémy Jaussaud, Zakaria Jalal, et al.. Heart rate response during exercise predicts exercise tolerance in adults with transposition of the great arteries and atrial switch operation. International Journal of Cardiology, 2020, 299, pp.116 - 122. 10.1016/j.ijcard.2019.07.054 . hal-03488612

# HAL Id: hal-03488612 https://hal.science/hal-03488612

Submitted on 21 Jul2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# Heart rate response during exercise predicts exercise tolerance in adults with transposition of the great arteries and atrial switch operation

- 4
- . 5 6

# <u>Authors</u>

Xavier Iriart, MD <sup>(1)</sup>\*, Soazig Le Quellenec, MD <sup>(1)</sup>; Xavier Pillois <sup>(2)</sup>; Jérémy Jaussaud MD <sup>(3)</sup>;
Zakaria Jalal, MD <sup>(1,2)</sup>; François Roubertie, MD, PhD <sup>(1,2)</sup>; Hervé Douard<sup>(5)</sup>, MD, PhD; Hubert Cochet,
MD, PhD <sup>(4,2)</sup>; and Jean- Benoît Thambo, MD, PhD <sup>(1,3)</sup>

10 11 <sup>(1)</sup> Department of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital, 33604 12 Pessac. France <sup>(2)</sup> LIRYC, L'institut de rythmologie et de modélisation cardiaque, Bordeaux University, France 13 <sup>(3)</sup> Clinique du sport, Mérignac, France 14 15 <sup>(4)</sup> Department of Cardiovascular imaging, Bordeaux University Hospital, 33604 Pessac, France <sup>(5)</sup> Cardiac Rehabilitation Department, Bordeaux University Hospital, 33604 Pessac, France 16 17 18 19 \*Corresponding author: 20 Iriart Xavier, MD Department of Pediatric and Adult Congenital Heart Disease 21 Bordeaux University Hospital, 33604 Pessac, France 22 E-mail address: xavier.iriart@chu-bordeaux.fr 23 24 25 Keywords - Cardiac magnetic resonance imaging; Cardiopulmonary exercise test; 26 Echocardiography; Exercise tolerance; Chronotropic incompetence; Transposition of the great 27 28 arteries 29 30 31 Conflicts of interest None

# 32 **1. INTRODUCTION**

33

Transposition of the Great Arteries (TGA) is one of the most common cyanotic heart defects 34 accounting for ~5% of all congenital heart diseases [1]. The Senning or the Mustard repair 35 provides a condition where the RV pumps through the systemic circulation resulting in the 36 morphological right ventricle being called systemic right ventricle (sRV). Senning and 37 Mustard surgery provides excellent results, with the large majority of patients with sRV 38 surviving until adulthood [2–6]. There are however a number of concerns regarding the long-39 term results [2][7], including exercise intolerance in a vast majority of those affected [8–11]. 40 Contradictory results have been observed regarding the correlation between sRV function 41 42 evaluated by echocardiography or Cardiac Magnetic Resonance Imaging (CMRI) and exercise intolerance [12–19]. Inadequate heart rate response to exercise (chronotropic 43 incompetence) is prevalent in this population and may play a role in this intolerance [20]. 44 45 The aim of the present study was to assess the relationship between heart rate response with

exercise capacity in adults with TGA after atrial repair operation in addition to the otherparameters obtained by the cardiopulmonary exercise test (CPET).

48 49

50

# 2. MATERIAL AND METHODS

This study was designed as a single-center retrospective analysis of data collected at a referral center of adult congenital heart disease (ACHD) at the Bordeaux Heart University Hospital, France. Data were collected retrospectively for all patients with sRV after atrial repair for TGA who underwent a CPET between 2015 and 2018. Clinical, electrocardiographic and laboratory data were documented at the day of the CPET. Cardiac imaging data, including transthoracic echocardiography or Magnetic resonance imaging (MRI) performed within a six-month time period of the CPET, were also collected. 58 Complex TGA was defined by associated intracardiac anomalies including ventricular 59 septal defect (VSD), left ventricular (pulmonary) outflow tract obstruction (LVOTO) or 60 coarctation of the aorta, as opposed to simple TGA. The study was performed in accordance 61 with the principles outlined in the declaration of Helsinki and was approved by the 62 Institutional Ethics Committee. All patients provided informed consent.

- 63
- 64

## 2.1 Cardiopulmonary exercise test protocol

All CPETs were performed on an upright cycle ergometer (Ergo Card, Medisoft, 65 Soriennes, Belgium) to assess maximal exercise capacity and maximal heart rate (HR) with 66 continuous monitoring of expiratory gases. Work load was increased by 10W/min or 67 30W/2min in a stepwise manner, depending on the individually predicted maximum exercise 68 capacity and in such a way that the calculated maximal effort was attained in ~10-15 min. 69 70 Oxygen consumption (VO2), ventilatory equivalent for O2 (VE/VO2 ratio) and ventilatory equivalent for CO2 (VE/VCO2), peak expiratory exchange ratio (VCO2/VO2), O2 pulse, 71 72 ratio of physiological dead space to tidal volume (VD/VT), ventilatory reserve (VR) and end-73 tidal CO2 tension (P<sub>ET CO2</sub>) were measured with a computerized breath-by-breath analyzer. Patient's maximal power output in watts, HR and systolic blood pressure (SBP) were also 74 recorded. The « circulatory power » (CP) was measured as the product of oxygen uptake and 75 arterial pressure following the Cohen-Solal method [21]. Exercise intolerance (functional 76 aerobic impairment) was defined as a peak oxygen uptake (%ppVO2) < 70% of predicted 77 value. The VE/VCO2 slope was calculated as a linear regression function, excluding the non-78 79 linear portion after the ventilatory compensation point. HR was measured by continuous electrocardiography. Arterial blood pressure was recorded manually at 2-minutes intervals by 80 81 sphymgomanometry. Patients were verbally encouraged to expend a maximal effort. All parameters were expressed as a percentage of the Wasserman predicted normal values [22]. 82

The first ventilatory anaerobic threshold (VAT) was determined according to the Wasserman 83 method [23] and expressed as a percentage of pVO2 and ppVO2. Age-predicted maximal HR 84 was calculated as (220 - age) [24]. Chronotropic responses were evaluated by heart rate 85 reserve (HRR), calculated as the difference between peak exercise HR and resting HR (peak 86 exercise HR – resting HR) and the age-adjusted HRR, calculated as the difference between 87 peak exercise HR and resting HR, divided by the difference of age-predicted maximal and 88 resting HR (HRR / [220-age-resting HR]). Chronotropic incompetence was defined using 89 established criteria as an age-adjusted HRR <80% or <62% on beta-blocker regimen [20]. 90

91 Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were
92 performed prior to exercise testing and are expressed as percentages of predicted values.
93 Patients in whom respiratory exchange ratio at peak exercise was < 1.1 were excluded from</li>
94 the study.

95

## 96 2.2 Echocardiography

97 All transthoracic echocardiographies (TTE) were performed with a Siemens SC2000 98 (Siemens Montain View, USA) using a 4v1c probe (phased array 1.5 to 4.3 MHz). 99 Assessment of RV function, pulmonary arterial hypertension and baffle status were assessed 100 semi quantitatively by an experienced echocardiographer. Systemic RV function was 101 evaluated by qualitative assessment of echocardiograms. Severity of systemic atrioventricular 102 valve (SAVV) regurgitation were graded by experienced physicians as trivial/mild, moderate 103 or severe.

The 2D area in systole and diastole was traced. Fractional area change (FAC) was calculated as  $FAC = 100 \times [(End diastolic area - end systolic area) / end diastolic area].$ Tricuspid annular plain systolic excursion (TAPSE) was measured in the apical 4-chamber view. Tricuspid annular plane systolic velocity (TAPSV) wave was measured using pulsed Doppler Tissue Imaging, with the Doppler sample volume placed in the tricuspid annulus of the RV free wall. Systemic RV global longitudinal strain (GLS) was quantified when conditions allowed. Left-Right or Right-Left shunt in the intra-atrial baffle obstruction to systemic venous and/or pulmonary venous drainage were diagnosed either with TTE with the use of Doppler techniques and contrast agents or CMR.

113 Systemic venous baffle obstruction was diagnosed as low flow velocity (<0.5 m/s) in 114 either the inferior vena cava or superior vena cava with flow >1.0 m/s in the baffle. 115 Pulmonary venous baffle obstruction was diagnosed if the peak velocity at the narrowest point 116 of the baffle was greater than 1.5 m/s [5]. LVOTO was determined using continuous wave 117 Doppler from the apical and 3- and 5-chamber views and was defined as peak aortic outflow 118 velocity > 2m/s.

119

121

120 2.3 Cardiac Magnetic Resonance

CMR studies were conducted on a 1.5 Tesla system (MAGNETOM Avanto, 122 SiemensHealthineers, Erlangen, Germany) equipped with a 32-channel cardiac coil. Cine 123 imaging was applied in a stack of contiguous slices encompassing both ventricles in short axis 124 using a retrospectively gated cine steady state free precession pulse sequence with the 125 following parameters: TR/TE 20/1.4ms, flip angle 60°, slice thickness 6 mm, pixel size 1.6 126 127 mm x 1.4 mm, and 30 frames per cardiac cycle. High resolution LGE imaging was performed approximately 17 min after contrast injection, using a 3-dimensional, inversion-recovery-128 129 prepared, ECG-gated, respiration-navigated gradient-echo pulse sequence with fat-saturation. Typical imaging parameters were: TR/TE, 6.1/2.4 ms; flip angle, 22°; voxel size, 1.25 Å~ 130 1.25 Å~ 2.5 mm; inversion time, 260-320 ms depending on the results of a TI scout scan 131 performed immediately before acquisition; parallel imaging using GRAPPA technique with R 132 133 = 2; 42 reference lines; acquisition time, 5-10 minutes depending on the patient's heart and breath rate. The processing of cine images was performed using Argus software (Siemens 134 Healthineers, Erlangen, Germany). An observer with 15 years' experience in CMR performed 135

all measurements. Ventricular end-diastolic volume (EDV), end-systolic volume (ESV) and
ejection fraction (EF) were derived from the segmentation of short axis images for the LV and
the RV.

139

# 140 **2.4 Statistical analysis**

Quantitative variables are expressed as means and standard deviations or as medians 141 and quartiles depending on their distribution. Analysis for quantitative variables was carried 142 out with the non-parametric Mann-Whitney test. Qualitative variables are expressed as 143 amounts and percentages. Nominal variables were analyzed with Fisher's exact test. Patients 144 were ranked in tertiles according to %ppVO2, due to the current lack of validated or 145 consensual cut-off values for %ppVO2 and given the limited number of patients expected to 146 147 be included. Differences between groups were analyzed using one-way ANOVA followed by a Bonferroni post-hoc test or Fisher's exact test. Statistical analysis was carried out comparing 148 these 3 groups (lower, middle, higher %ppVO2 tertiles). Logistic regression testing with 149 forward and backward selection and Spearman rank correlation coefficient was applied in the 150 univariate analysis. All statistical tests were 2-sided and a p value < 0.05 was considered 151 statistically significant. 152

153

### 154 **3. RESULTS**

155

# 156 **3.1 Patient characteristics**

157 Ninety-eight patients with a sRV for TGA after atrial switch repair were identified in 158 our institutional database during the study period. Twenty-eight patients were excluded due to 159 unavailable CPET data or were non-interpretable for technical reasons or because respiratory 160 exchange ratio at peak exercise was < 1.1, resulting in 70 patients being ultimately studied 161 (mean of age  $32.4 \pm 7.6$  years old, 51 males). The baseline data for the study cohort are 162 presented in Table A.

163

## 164 **3.2 Cardiac resting imaging**

All patients had a TTE and a CMR was performed in 56 patients. The mean CMR RV 165 Ejection Fraction (RVEF) was 49.1 ± 9.8%, mean RV FAC was 34.6 +/- 7.4% and mean GLS 166 was -11.9 + 2.2%. Two patients had severe systemic atrioventricular valve (SAVV) 167 168 regurgitation, ten had moderate regurgitation and the remainder had trivial to mild regurgitation. Leak baffle was found in 4 patients and baffle stenosis in 4 patients. Twenty-169 two patients had LVOTO. No significant differences in resting parameters of systolic sRV 170 171 function were observed across the tertiles and there was no correlation between resting cardiac function and ppVO2% (CMR RV EF: r=0.124, p=0.362; TAPSV: r=0.178, p=0.56; 172 FAC: r=0.282, p=0.124; Strain: r=-0.077, p=0.639). Quantitative measurements of sRV 173 function assessed by TEE and MRI and late gadolinium enhancement data are shown in Table 174 B. 175

176

177 **3.3 Cardiopulmonary exercise testing** 

Patient characteristics were assessed according to tertiles of the % ppVO2 (Tables C) which resulted in categories of %ppVO2 > 62% (upper tertile, 22 patients, group 3), 52 to 62% (middle tertile, 22 patients, group 2) and  $\leq$  51% (lower tertile, 26 patients, group 1).

All data of CPET are presented in appendix 1 (supplemental data). Mean pVO2 was 21.5  $\pm$  5.8 mL/kg/min, corresponding to a 57  $\pm$  14.1% of predicted values. The median %ppVO2 in the three tertiles were 72.7, 57.2 and 43.4%, respectively for groups 3, 2 and 1. Mean % of predicted peak oxygen pulse was 63.9  $\pm$  18.2% for a normal > 70% and was significantly different between the 1<sup>st</sup> and 3<sup>rd</sup> tertiles. There was no significant correlation

between % of predicted peak O2 pulse and the %ppVO2 (r=0.23; p=0.148). The oxygen pulse 186 coefficient was significantly different between the 3<sup>rd</sup> tertile and the other two tertiles and 187 there was a moderate correlation with %ppVO2 (r=0.494; p<0.001). A significant exaggerated 188 hyperventilation was observed in the study population with a VE/VCO2 slope of 37.1. Peak 189 circulatory power was 3536.9 ± 1227.5 mmHg.ml O2.min-1.kg-2. No reference values were 190 validated, although a prognostic cut-off of < 1476 mm Hg mlO2.min-1.kg-2 was proposed by 191 Giardini et al. as this cut-off was associated with a 15.4-fold increase in the 4-year risk of 192 death in adult congenital heart disease [25]. 193

Peak SBP was considered normal without significant differences across tertiles whereas the peak to resting SBP gradient was significantly different between the 1<sup>st</sup> tertile and the other two tertiles. Peak SBP and SBP gradient were correlated with %ppVO2 (r=0.284, p=0.018 and r=0.382, p=0.001 respectively).

None of the patients had electrocardiographic changes suggestive of myocardial
ischemia during exercise or recovery. One patient had transient exercise-induced high degree
atrioventricular block and subsequently underwent a pacemaker implantation.

201 NYHA functional class was correlated with %ppVO2 (r=-0.49, p<0.001) and was</li>
 202 significantly different across tertiles.

FEV1 was > 80% of predicted values as was the FEV1/FCV ratio, indicating that these
patients had no pulmonary obstructive disease.

Although patients had a slightly decreased mean FCV (78,6  $\pm$  14.2%, normal > 80% predicted value), the data showed no correlation between FCV and peak VO2.

207 VD/VT ratio decreased at stress while Ventilatory reserve was > 30% in the 3 tertiles 208 with no significant difference between the three groups. There was a significant difference in P<sub>ET</sub> 209 co<sub>2</sub> at VAT between group 1 and 3 (p = 0.044) and in VD/VT at peak between the same 210 groups (p = 0.009). 211 Mean VE/VCO2 slope was 37.1 ± 8.2 whereas a VE/VCO2 slope < 30 is considered</li>
212 normal without modification for age and sex [26].

213	VAT was determined for 67 patients and was decreased throughout the cohort,
214	reaching 5'10'' $\pm$ 2'. Mean value was 13.4 $\pm$ 3.6 mL/min/kg, with 61.8 $\pm$ 13.4 % of pVO2 and
215	$35.4 \pm 10.8$ % of ppVO2. A value < 40% of predicted peak VO2 generally suggests muscle
216	deconditioning and was correlated with %ppVO2 (r=0.571; p<0.001). VAT was > 40% only
217	in group 3.

218

## 219 **3.4 Impact of cardiac rhythm on exercise capacity**

- The mean heart rate reserve value was  $84.7 \pm 25.4$  and mean age-adjusted HRR was  $68.5 \pm 19$ . Peak heart rate was  $148.6 \pm 26.2$  bpm.
- 222 Chronotropic incompetence (CI) was found in 65.7% of patients as a whole, with
  223 76.9% in group 1, 77.3% in group 2 and 38.1% in group 3.
- CI was associated with lower %ppVO2 (statistical difference between  $1^{st}$  or  $2^{nd}$  and  $3^{rd}$ tertile) and age-adjusted HRR was correlated with %ppVO2 (r=0.482; p<0,001) as was peak heart rate (r=0.457, p<0.001) (Tables C).

227 Seventeen patients treated with beta-blockers (77%) and 13 patients having a 228 pacemaker (86.6%) showed chronotropic incompetence. Beta-blocker treatment and the 229 presence of a pacemaker appeared to be associated with a limitation in %ppVO2 (significant 230 difference between 1<sup>st</sup> and 3<sup>rd</sup> tertiles).

231

## **4. DISCUSSION**

233

Exercise capacity is known to be impaired in adults with sRV after a TGA atrial repair [8–11]. Aerobic functional performance requires integrated cardiovascular, pulmonary and skeletal muscle physiology. Abnormal function in any one of these systems diminishes pVO2
and increases ventilatory equivalents [27]. The Fick equation states that oxygen uptake equals
cardiac output times the arterial minus mixed venous oxygen content (C(A-V) O2). Exercise
intolerance could hence be related to one or both of these factors and to the variables that
influence them.

241

## 242 **4.1 Involvement of limited HRR to exercise intolerance**

Chronotropic incompetence defined by age-adjusted HRR was directly correlated with
%ppVO2. The degree of chronotropic incompetence was a major determinant of exercise
intolerance in this population.

In healthy humans, the increase in VO2 is achieved by a 2.5 to 3.2-fold increase in cardiac output and a 1.5 to 2.5-fold increase in C(A-V) O2. The increase in cardiac output results from a 2.2 to 2.5-fold increase in heart rate and a 0.3 to 1.4-fold increase in stroke volume [28–30]. Thus, the increase in HR is the strongest contributor to the ability to perform sustained aerobic exercise. It is therefore not surprising that chronotropic incompetence can be the primary cause or a significant contributor to severe, symptomatic exercise intolerance [24][31][32].

In adults with sRV after TGA atrial redirection, various causes may explain chronotropic incompetence. Sinus node dysfunction after atrial switch procedures is common (prevalence ~ 60% at 20 years of follow-up) [33]. It is seemingly caused by sinus node/atrial conduction tissue damage or interruption of sinus node blood flow during surgery [34]. This could be of major importance since treatment optimization, as well as pacemaker parameter adjustment, could benefit these patients. The inability to reach an age-adjusted HRR > 80% in the study was associated with antiarrhythmic or beta-blocker therapy in parallel with a decrease in %ppVO2. These drugs have been poorly studied in this population and their beneficial effects remain equivocal [35][36]. The present study findings suggest that they may have a negative effect on exercise capacity while their effects on mortality and morbidity are yet to be well established. In adults with CHD and frequent recurrent symptomatic supraventricular tachycardia, ablation strategy may be preferable to a long-term pharmacologic therapy as stated by the PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease [33][37]

267

#### **4.2 Involvement of stroke volume augmentation to exercise intolerance**

O2 pulse is the instantaneous ratio of VO2 and HR. It reflects the stroke volume and peripheral oxygen extraction response to increasing workload during exercise. The present findings showed a correlation between the increase in oxygen pulse and ppVO2% suggesting that a part of exercise limitation was also due to an inadequate response of stroke volume to effort in addition to the peripheral limitation.

Ventricular stroke output is regulated by three factors: preload, the contractile state of the myocardium and afterload stress [29]. Preload might play a role since ventricular filling may be inadequate through the atrial baffle and further worsened by abnormal sRV compliance secondary to chronic RV hypertrophy. Furthermore, atrial blood redirection after surgery can be modified by baffle leaks or baffle obstruction. Derrick et al. suggested that the major limiting factor of stroke volume augmentation during exercise was an impaired ventricular filling in adults with TGA after atrial redirection [38].

sRV inotropic response to exercise is another main determinant of cardiac output augmentation at exercise. Systemic RV exhibits unique myocardial mechanics, with a shift toward a more predominant circumferential free wall shortening compared to subpulmonary RV, but with lack of normal torsion [16]. It may also be affected by ischemia and fibrosis. RV

myocardial ischemia is common in this particular setting, the reason likely being 285 multifactorial. The branching pattern of the major coronary vessels is often abnormal in this 286 condition. In addition, ischemia may be further increased [39] by a metabolic imbalance given 287 that the right coronary arterial system may not supply adequate flow to the hypertrophied 288 systemic RV, thus providing a substrate for the development of progressive ischemic damage 289 [39][40]. Fibrosis may additionally be a consequence of ischemia but also of preoperative 290 cyanosis as well as of the surgery itself. Younger patients have been reported to exhibit a 291 292 lower degree of myocardial fibrosis, possibly as a result of improvements in cardiothoracic surgery, including the advent of cold cardioplegia and cardiopulmonary bypass [41]. 293 Notwithstanding, this study showed no association between resting systolic sRV function and 294 exercise capacity. Neither CMR RV Ejection Fraction nor other TTE-measured parameters 295 were correlated with %ppVO2. Reported data on the relationship between resting RVEF and 296 297 exercise capacity in patients with sRV are inconsistent. Indeed, whereas Ladouceur et al. reported a low to moderate correlation between longitudinal strain and exercise capacity [17], 298 299 recent studies with advanced CMR techniques including longitudinal and circumferential 300 strain showed poor to absence of correlation [13-18] between function resting parameters and exercise capacity. This suggests that a resting imaging follow-up alone may be insufficient to 301 explore exercise intolerance [19]. Moreover, afterload did not appear of critical importance in 302 the present population since patients were relatively young and did not present resting or 303 304 exercise arterial hypertension.

305

## **306 4.3 Ventilatory response and lung function**

We did not find evidence of ventilatory or pulmonary vascular limitation in our study cohort. Mean FVC was slightly decreased ( $78.6 \pm 14.2\%$ ) and 57.3% of patients had a FVC <80%. A diminished FVC could be predictive of a restrictive respiratory pattern, although the</li>
diagnosis was made by the Total Lung Capacity which was not measured.

311

## **4.4 Peripheral vascular and skeletal muscle bulk and functions**

Peak VO2 is also determined by peripheral factors [42]. VAT usually occurs at 313 approximately 45% to 65% of peak VO2 in healthy untrained subjects [43]. In the present 314 study, 73.5% of our patients had a VAT < 40% of predicted peak VO2 and was statistically 315 associated with VO2 limitation. It has been shown that decreased exercise cardiac output 316 probably causes skeletal muscle hypoperfusion, which is a potent stimulus for early anaerobic 317 318 metabolism, and subsequent generation of muscle lactate and other metabolites that can produce the sensation of peripheral and central fatigue [44]. There is also a relatively high 319 incidence of a sedentary lifestyle and physical deconditioning in this population resulting in 320 their peripheral large muscles being unable to maximize extraction of oxygen and influencing 321 peak exercise capacity [45]. Randomized trials have shown that a training protocol could 322 323 improve peak oxygen consumption in this adult population with sRV / TGA [42][46].

324

325 **4.5 Strengths and limitations** 

This study has several limitations inherent to any retrospective study. Adults with TGA comprise approximately only 1.6% of all adult congenital patients. Given the singlecenter nature of this study, its power was limited by the small number of included patients, as could its generalizability. Despite this latter drawback, the present study population represented one of the largest cohorts on TGA after atrial redirection. A selection bias may have occurred as patients were recruited at a tertiary center. Therefore, we cannot exclude the possibility that it represented a biased sample, favoring patients with more symptoms and lower perceived functional capacity.

A registry search with IC10 codes could also have led to a selection bias by missing some patients classified under other codes. In order to limit this bias, an extensive list of IC10 codes was used after which medical records were meticulously analyzed by the same researcher.

338 Finally, it could be argued that chronotropic incompetence is the main factor of exercise

intolerance as long as the cardiac function of the ventricle is relatively preserved, which is the
case in our relatively young population, and we cannot exclude that progressive weakening of
systemic ventricle function may play a larger role as the population ages.

## 342 **5. CONCLUSION**

Adults with TGA after atrial redirection had exercise intolerance due to a limitation of cardiac output augmentation at exercise which was multifactorial, including chronotropic intolerance, muscle deconditioning and impaired cardiac hemodynamics throughout exercise testing. Resting imaging data were not predictive of the hemodynamic adaptation to exercise. The inability to increase cardiac output during exercise was notably due to incompetent chronotropic response which is predominant in this population. 349

# 350 6. FUNDING SOURCES

351 This research did not receive any specific grant from funding agencies in the public,

352 commercial, or not-for-profit sectors.

353

# 354 7. CONFLICTS OF INTEREST

355 None.

# 356 **8. REFERENCES**

- M. Šamánek, Z. Slavík, B. Zbořilová, V. Hroboňová, M. Voříšková, J. Škovránek, Prevalence,
  treatment, and outcome of heart disease in live-born children: A prospective analysis of 91,823
  live-born children, Pediatr. Cardiol. 10 (1989) 205–211. doi:10.1007/BF02083294.
- F. Roubertie, J.-B. Thambo, A. Bretonneau, X. Iriart, N. Laborde, E. Baudet, X. Roques, Late
  Outcome of 132 Senning Procedures After 20 Years of Follow-Up, Ann. Thorac. Surg. 92
  (2011) 2206–2214. doi:10.1016/j.athoracsur.2011.06.024.
- J.A.A.E. Cuypers, J.A. Eindhoven, M.A. Slager, P. Opić, E.M.W.J. Utens, W.A. Helbing, M.
  Witsenburg, A.E. Van Den Bosch, M. Ouhlous, R.T. Van Domburg, D. Rizopoulos, F.J.
  Meijboom, A.J.J.C. Bogers, J.W. Roos-Hesselink, The natural and unnatural history of the
  Mustard procedure: Long-term outcome up to 40 years, Eur. Heart J. 35 (2014) 1666–1674.
  doi:10.1093/eurheartj/ehu102.
- P. Moons, Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium, Heart. 90 (2004) 307–313.
  doi:10.1136/hrt.2002.007138.
- M. Dennis, I. Kotchetkova, R. Cordina, D.S. Celermajer, Long-Term Follow-up of Adults
  Following the Atrial Switch Operation for Transposition of the Great Arteries A
  Contemporary Cohort, Hear. Lung Circ. (2017). doi:10.1016/j.hlc.2017.10.008.
- N. Vejlstrup, K. Sørensen, E. Mattsson, U. Thilén, P. Kvidal, B. Johansson, K. Iversen, L.
  Søndergaard, M. Dellborg, P. Eriksson, Long-term outcome of mustard/senning correction for
  transposition of the great arteries in Sweden and Denmark, Circulation. 132 (2015) 633–638.
  doi:10.1161/CIRCULATIONAHA.114.010770.
- 378 [7] C.A. Warnes, Transposition of the great arteries, Circulation. 114 (2006) 2699–2709.
  379 doi:10.1161/CIRCULATIONAHA.105.592352.
- S.J. Hechter, G. Webb, P.M. Fredriksen, L. Benson, N. Merchant, M. Freeman, G. Veldtman,
  M.A. Warsi, S. Siu, P. Liu, Cardiopulmonary exercise performance in adult survivors of the
  Mustard procedure, Cardiol. Young. 11 (2001) 407. doi:10.1017/S104795110100052X.
- A. Giardini, A. Hager, A.E. Lammers, G. Derrick, J. Müller, G.P. Diller, K. Dimopoulos, D.
  Odendaal, G. Gargiulo, F.M. Picchio, M.A. Gatzoulis, Ventilatory Efficiency and Aerobic
  Capacity Predict Event-Free Survival in Adults With Atrial Repair for Complete Transposition
  of the Great Arteries, J. Am. Coll. Cardiol. 53 (2009) 1548–1555.
  doi:10.1016/j.jacc.2009.02.005.
- T. Reybrouck, M. Gewillig, M. Dumoulin, L.G. Van Der Hauwaert, Cardiorespiratory exercise
   performance after Senning operation for transposition of the great arteries, Br. Heart J. 70
   (1993) 175–179. http://www.scopus.com/inward/record.url?eid=2-s2.0-
- 3910027237011&partnerID=40&md5=53bfa197de99e49843f5417d1c18f13e%5Cnhttp://ovidsp.o392vid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed3&NEWS=N&AN=1993248049.
- V. Mantegazza, A. Apostolo, A. Hager, Cardiopulmonary Exercise Testing in Adult Congenital
   Heart Disease, Ann. Am. Thorac. Soc. 14 (2017) S93–S101. doi:10.1513/AnnalsATS.201611 876FR.
- J.W. Roos-Hesselink, F.J. Meijboom, S.E.C. Spitaels, R. Van Domburg, E.H.M. Van Rijen,
  E.M.W.J. Utens, J. McGhie, E. Bos, A.J.J.C. Bogers, M.L. Simoons, Decline in ventricular
  function and clinical condition after mustard repair for transposition of the great arteries (a
  prospective study of 22-29 years), Eur. Heart J. 25 (2004) 1264–1270.
  doi:10.1016/j.ehj.2004.03.009.
- 401 [13] W. Li, T.S. Hornung, D.P. Francis, C. O'Sullivan, A. Duncan, M. Gatzoulis, M. Henein,

- 402 Relation of Biventricular Function Quantified by Stress Echocardiography to Cardiopulmonary
  403 Exercise Capacity in Adults With Mustard (Atrial Switch) Procedure for Transposition of the
  404 Great Arteries, Circulation. 110 (2004) 1380–1386.
  405 doi:10.1161/01.CIR.0000141370.18560.D1.
- K. Norozi, R. Buchhorn, V. Alpers, J.O. Arnhold, S. Schoof, M. Zoege, S. Geyer, A. Wessel,
  Relation of systemic ventricular function quantified by myocardial performance index (Tei) to
  cardiopulmonary exercise capacity in adults after mustard procedure for transposition of the
  great arteries, Am. J. Cardiol. 96 (2005) 1721–1725. doi:10.1016/j.amjcard.2005.07.096.
- P. Roentgen, M. Kaan, O. Tutarel, G.P. Meyer, M. Westhoff-Bleck, Declining
  cardiopulmonary exercise capacity is not associated with worsening systolic systemic
  ventricular dysfunction in adults with transposition of great arteries after atrial switch
  operation, Congenit. Heart Dis. 9 (2014) 259–265. doi:10.1111/chd.12137.
- K.M. Shafer, N. Mann, R. Hehn, A. Ubeda Tikkanen, A.M. Valente, T. Geva, N. Gauthier, J.
  Rhodes, Relationship between Exercise Parameters and Noninvasive Indices of Right
  Ventricular Function in Patients with Biventricular Circulation and Systemic Right Ventricle,
  Congenit. Heart Dis. 10 (2015) 457–465. doi:10.1111/chd.12248.
- 418 [17] M. Ladouceur, A. Redheuil, G. Soulat, C. Delclaux, M. Azizi, M. Patel, G. Chatellier, A.
  419 Legendre, L. Iserin, Y. Boudjemline, D. Bonnet, E. Mousseaux, Longitudinal strain of systemic 420 right ventricle correlates with exercise capacity in adult with transposition of the great arteries 421 after atrial switch, Int. J. Cardiol. 217 (2016) 28–34. doi:10.1016/j.ijcard.2016.04.166.
- [18] O. Tutarel, S. Orwat, R.M. Radke, M. Westhoff-bleck, C. Vossler, C. Schülke, H.
  Baumgartner, J. Bauersachs, P. Röntgen, G. Diller, Assessment of myocardial function using
  MRI-based feature tracking in adults after atrial repair of transposition of the great arteries :
  Reference values and clinical utility, Int. J. Cardiol. 220 (2016) 246–250.
  doi:10.1016/j.ijcard.2016.06.108.
- F. Helsen, P. De Meester, A. Van De Bruaene, C. Gabriels, B. Santens, M. Claeys, G.
  Claessen, K. Goetschalckx, R. Buys, M. Gewillig, E. Troost, J.-U. Voigt, P. Claus, J. Bogaert,
  W. Budts, Right ventricular systolic dysfunction at rest is not related to decreased exercise
  capacity in patients with a systemic right ventricle, Int. J. Cardiol. 260 (2018) 66–71.
  doi:10.1016/j.ijcard.2018.03.029.
- 432 [20] G.P. Diller, D.O. Okonko, A. Uebing, K. Dimopoulos, S. Bayne, R. Sutton, D.P. Francis, M.A.
  433 Gatzoulis, Impaired heart rate response to exercise in adult patients with a systemic right
  434 ventricle or univentricular circulation: Prevalence, relation to exercise, and potential
  435 therapeutic implications, Int. J. Cardiol. 134 (2009) 59–66. doi:10.1016/j.ijcard.2008.01.032.
- 436 [21] A. Cohen-Solal, J.Y. Tabet, D. Logeart, P. Bourgoin, M. Tokmakova, M. Dahan, A non-invasively determined surrogate of cardiac power ('circulatory power') at peak exercise is a powerful prognostic factor in chronic heart failure, Eur. Heart J. 23 (2002) 806–814.
  439 doi:10.1053/euhj.2001.2966.
- 440 [22] K. Wasserman, J. Hansen, D. Sue, B. Whipp, Principles of Exercise Testing and Interpretation:
  441 Including Pathophysiology and Clinical Applications, 3Rd Edition, Shock. 14 (2000) 80.
  442 doi:10.1097/00024382-200014010-00017.
- 443 [23] K. Wasserman, Determinants and detection of anaerobic threshold and consequences of
  444 exercise above it., Circulation. 76 (1987) VI29-39.
  445 http://www.ncbi.nlm.nih.gov/pubmed/3315297 (accessed May 24, 2018).
- 446 [24] P.H. Brubaker, D.W. Kitzman, Chronotropic incompetence: causes, consequences, and
  447 management., Circulation. 123 (2011) 1010–20.
  448 doi:10.1161/CIRCULATIONAHA.110.940577.

- 449 [25] A. Giardini, S. Specchia, E. Berton, D. Sangiorgi, G. Coutsoumbas, G. Gargiulo, G. Oppido,
  450 M. Bonvicini, F.M. Picchio, Strong and independent prognostic value of peak circulatory
  451 power in adults with congenital heart disease, Am. Heart J. 154 (2007) 441–447.
  452 doi:10.1016/j.ahj.2007.05.009.
- 453 [26] X.-G. Sun, J.E. Hansen, N. Garatachea, T.W. Storer, K. Wasserman, Ventilatory Efficiency
  454 during Exercise in Healthy Subjects, Am. J. Respir. Crit. Care Med. 166 (2002) 1443–1448.
  455 doi:10.1164/rccm.2202033.
- 456 [27] G.J. Balady, R. Arena, K. Sietsema, J. Myers, L. Coke, G.F. Fletcher, D. Forman, B. Franklin, M. Guazzi, M. Gulati, S.J. Ketevian, C.J. Lavie, R. Macko, D. Mancini, R. V Milani, American 457 Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council 458 on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Peripheral 459 460 Vascular Disease, Interdisciplinary Council on Quality of Care and Outcomes Research, 461 Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association., Circulation. 122 (2010) 191-225. 462 463 doi:10.1161/CIR.0b013e3181e52e69.
- 464 [28] D.W. Kitzman, Exercise intolerance, Prog. Cardiovasc. Dis. 47 (2005) 367–379.
   465 doi:10.1016/j.pcad.2005.02.002.
- 466 [29] M.B. Higginbotham, K.G. Morris, R.S. Williams, P.A. McHale, R.E. Coleman, F.R. Cobb,
  467 Regulation of stroke volume during submaximal and maximal upright exercise in normal man.,
  468 Circ. Res. 58 (1986) 281–91. http://www.ncbi.nlm.nih.gov/pubmed/3948345 (accessed May
  469 23, 2018).
- 470 [30] M.J. Sullivan, F.R. Cobb, M.B. Higginbotham, Stroke volume increases by similar 471 mechanisms during upright exercise in normal men and women., Am. J. Cardiol. 67 (1991) 472 1405–12. http://www.ncbi.nlm.nih.gov/pubmed/2042572 (accessed June 5, 2018).
- 473 [31] M.M. Winter, M.N. Van Der Plas, B.J. Bouma, M. Groenink, P. Bresser, B.J.M. Mulder,
  474 Mechanisms for cardiac output augmentation in patients with a systemic right ventricle, Int. J.
  475 Cardiol. 143 (2010) 141–146. doi:10.1016/j.ijcard.2009.01.065.
- 476 [32] S. Fratz, A. Hager, R. Busch, H. Kaemmerer, M. Schwaiger, R. Lange, J. Hess, H.C. Stern,
  477 Patients after atrial switch operation for transposition of the great arteries can not increase
  478 stroke volume under dobutamine stress as opposed to patients with congenitally corrected
  479 transposition., Circ. J. 72 (2008) 1130–5. http://www.ncbi.nlm.nih.gov/pubmed/18577823
  480 (accessed May 20, 2019).
- [33] P. Khairy, G.F. Van Hare, S. Balaji, C.I. Berul, F. Cecchin, M.I. Cohen, C.J. Daniels, B.J.
  Deal, J.A. Dearani, N. de Groot, A.M. Dubin, L. Harris, J. Janousek, R.J. Kanter, P.P.
  Karpawich, J.C. Perry, S.P. Seslar, M.J. Shah, M.J. Silka, J.K. Triedman, E.P. Walsh, C.A.
  Warnes, PACES/HRS Expert Consensus Statement on the Recognition and Management of
  Arrhythmias in Adult Congenital Heart Disease, Can. J. Cardiol. 30 (2014) e1–e63.
  doi:10.1016/j.cjca.2014.09.002.
- L. Dos, L. Teruel, I.J. Ferreira, J. Rodriguez-Larrea, L. Miro, J. Girona, D.C. Albert, A.
  Gonçalves, M. Murtra, J. Casaldaliga, Late outcome of Senning and Mustard procedures for
  correction of transposition of the great arteries, Heart. 91 (2005) 652–656.
  doi:10.1136/hrt.2003.029769.
- 491 [35] P. Khairy, Sudden cardiac death in transposition of the great arteries with a Mustard or Senning
  492 baffle: The myocardial ischemia hypothesis, Curr. Opin. Cardiol. 32 (2017) 101–107.
  493 doi:10.1097/HCO.000000000353.
- 494 [36] A. Giardini, L. Lovato, A. Donti, R. Formigari, G. Gargiulo, F.M. Picchio, R. Fattori, A pilot
  495 study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in
  496 patients with systemic right ventricle, Int. J. Cardiol. 114 (2007) 241–246.

- doi:10.1016/j.ijcard.2006.01.048.
- F. Akca, T. Bauernfeind, M. Witsenburg, L. Dabiri Abkenari, J.A. Cuypers, J.W. RoosHesselink, N.M.S. de Groot, L. Jordaens, T. Szili-Torok, Acute and Long-Term Outcomes of
  Catheter Ablation Using Remote Magnetic Navigation in Patients With Congenital Heart
  Disease, Am. J. Cardiol. 110 (2012) 409–414. doi:10.1016/j.amjcard.2012.03.040.
- [38] G.P. Derrick, I. Narang, P.A. White, A. Kelleher, A. Bush, D.J. Penny, A.N. Redington, Failure of stroke volume augmentation during exercise and dobutamine stress is unrelated to load-independent indexes of right ventricular performance after the Mustard operation., Circulation. 102 (2000) III154-9. http://www.ncbi.nlm.nih.gov/pubmed/11082379 (accessed June 10, 2018).
- 507 [39] T.S. Hornung, P.J. Kilner, P.A. Davlouros, F. Grothues, W. Li, M.A. Gatzoulis, Excessive right
  508 ventricular hypertrophic response in adults with the mustard procedure for transposition of the
  509 great arteries, Am. J. Cardiol. 90 (2002) 800–803. doi:10.1016/S0002-9149(02)02619-X.
- 510 [40] T. Millane, E.J. Bernard, E. Jaeggi, R.B. Howman-Giles, R.F. Uren, T.B. Cartmill, R.E.
  511 Hawker, D.S. Celermajer, Role of ischemia and infarction in late right ventricular dysfunction 512 after atrial repair of transposition of the great arteries., J. Am. Coll. Cardiol. 35 (2000) 1661–8.
  513 http://www.ncbi.nlm.nih.gov/pubmed/10807474 (accessed May 27, 2018).
- [41] S. V. Babu-Narayan, O. Goktekin, J.C. Moon, C.S. Broberg, G.A. Pantely, D.J. Pennell, M.A.
  Gatzoulis, P.J. Kilner, Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries, Circulation. 111 (2005) 2091–2098. doi:10.1161/01.CIR.0000162463.61626.3B.
- [42] M.M. Winter, T. van der Bom, L.C.S. de Vries, A. Balducci, B.J. Bouma, P.G. Pieper, A.P.J.
  van Dijk, M.N. van der Plas, F.M. Picchio, B.J.M. Mulder, Exercise training improves exercise
  capacity in adult patients with a systemic right ventricle: a randomized clinical trial, Eur. Heart
  J. 33 (2012) 1378–1385. doi:10.1093/eurheartj/ehr396.
- 522 [43] J.A. Davis, P. Vodak, J.H. Wilmore, J. Vodak, P. Kurtz, Anaerobic threshold and maximal
  523 aerobic power for three modes of exercise, J. Appl. Physiol. 41 (1976) 544–550.
  524 doi:10.1152/jappl.1976.41.4.544.
- 525 [44] M.J. Sullivan, F.R. Cobb, The anaerobic threshold in chronic heart failure. Relation to blood lactate, ventilatory basis, reproducibility, and response to exercise training., Circulation. 81 (1990) II47-58. http://www.ncbi.nlm.nih.gov/pubmed/2295152 (accessed June 5, 2018).
- Fredriksen, E. Ingjer, E. Thaulow, Physical activity in children and adolescents with congenital heart disease. Aspects of measurements with an activity monitor., Cardiol. Young. 10 (2000) 98–106. http://www.ncbi.nlm.nih.gov/pubmed/10817292 (accessed May 25, 2018).
- [46] W. Roest, H.J. Lamb, E.E. van der Wall, H.W. Vliegen, J.G. van den Aardweg, P. Kunz, A. de
  Roos, W. a Helbing, Cardiovascular response to physical exercise in adult patients after atrial
  correction for transposition of the great arteries assessed with magnetic resonance imaging.,
  Heart. 90 (2004) 678–684. doi:10.1136/hrt.2003.023499.

535

# Tables

# **Table A: Patient characteristics**

Age, years       32,4 +/- 7,6         Male gender       51 (72,9)         Senning procedure       57 (81,4)         Mustard procedure       13 (18,6)         Complexe TGA       19 (27,1)         Age repair, month       7,3 +/- 5,4         Body Mass Index, kg.m-2       24,8 +/- 5,5         NYHA functional class       1,4 +/- 0,7         O2 saturation, %       97,3 +/- 2,1         Medication       22 (31,4)         ACE-I/ARBs/ARNI/Aldosterone antagonist       21 (30)         Loop diuretic       6 (8,6)         Antiarrhythmic       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Khythm history       27 (38,6)         Kinioventricular block       8 (11,4)         Ventricular arrhythmias       14 (20)         Supraventricular arrhythmias       14 (20)         Supraventricular arrhythmias       31 (44,3)		N = 70			
Male gender       51 (72.9)         Senning procedure       57 (81.4)         Mustard procedure       13 (18.6)         Complexe TGA       19 (27.1)         Age repair, month       73 +/- 5.4         Body Mass Index, kg.m-2       248 +/- 5.5         NYHA functional class       14 +/- 0.7         O2 saturation, %       97,3 +/- 2.1         ACE-IVARBS/ARNI/Aldosterone antagonis       21 (30)         ACE-IVARBS/ARNI/Aldosterone antagonis       21 (30)         Katiarrhythmia       64.6,6)         Instander (Dual chamber or CRT)       15 (21.4)         Pacemaker (Dual chamber or CRT)       51 (31.6)         Kinis nonde dysfunction       27 (38.6)         Kinis nonde dysfunction       14 (20)         Kinis nontet dysfunction       14 (20)	Age, years	32,4 +/- 7,6			
Senning procedure       57 (81,4)         Mustard procedure       13 (18,6)         Complexe TGA       19 (27,1)         Age repair, month       7,3 +/- 5,4         Body Mass Index, kg.m-2       24,8 +/- 5,5         NYHA functional class       14 +/- 0,7         O2 saturation, %       97,3 +/- 2,1         Medication       14 +/- 0,7         Acterion       22 (31,4)         ACE-I/ARBs/ARNI/Aldosterone antagonis       21 (30)         Acterion       21 (30)         Ratiarthythmic       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Fuptim Listory       27 (38,6)         Minoventricular block       8 (11,4)         Ventricular arrhythmic       14 (20)         Kipraventricular arrhythmic       14 (20)	Male gender	51 (72,9)			
Mustard procedure13 (18,6)Complexe TGA19 (27,1)Age repair, month7,3 +/- 5,4Body Mass Index, kg.m-224,8 +/- 5,5NYHA functional class1,4 +/- 0,7O2 saturation, %9,7 3 +/- 2,1 <b>Medication</b> 9,7 3 +/- 2,1Acte-IvARBs/ARNI/Aldosterone antagonis21 (30)ACE-I/ARBs/ARNI/Aldosterone antagonis21 (30)Acte-IvARBs/ARNI/Aldosterone antagonis6 (8,6)Acte-IvARBs/ARNI/Aldosterone antagonis13 (18,6)Pacemaker (Dual chamber or CRT)15 (21,4)Fuptim history15 (21,4)Sinus node dysfunction3 (14,6)Kurioventricular arbhytmis14 (20)Supraventricular archytmis31 (44,5)BNP, ng/L78,1 +/- 80,7	Senning procedure	57 (81,4)			
Complexe TGA       19 (27,1)         Age repair, month       7,3 +/- 5,4         Body Mass Index, kg.m-2       24,8 +/- 5,5         NYHA functional class       1,4 +/- 0,7         O2 saturation, %       97,3 +/- 2,1 <b>Medication</b> 97,3 +/- 2,1         Acteriton, %       22 (31,4)         Acteriton       21 (30,1)         Acteriton       31 (30,2)         Acteriton       31 (42,1)         Acteriton       31 (42,1)         Acteriton       31 (42,1)         Actionation       31 (42,1)         Actionation       31 (42,1)         Actionation       31 (42,1)         Actionation       31 (42,1)	Mustard procedure	13 (18,6)			
Age repair, month7,3 +/- 5,4Body Mass Index, kg.m-224,8 +/- 5,5NYHA functional class1,4 +/- 0,7O2 saturation, %97,3 +/- 2,1 <b>Medication</b> 97,3 +/- 2,1 <b>Medication</b> 22 (31,4)ACE-I/ARBs/ARNI/Aldosterone antagonis21 (30)Loop diureti6 (8,6)ACE-I/ARBs/ARNI/Aldosterone antagonis13 (18,6)Pacemaker (Dual chamber or CRT)15 (21,4)Futythm history15 (21,4)Sinus node dysfunction8 (11,4)Khythm history14 (20)Supraventricular arthythmia14 (20)Supraventricular arthythmia31 (44,3)BNP, ng/L58 (1-2, 10)	Complexe TGA	19 (27,1)			
Body Mass Index, kg.m-2       24,8 +/-5,5         NYHA functional class       1,4 +/- 0,7         O2 saturation, %       97,3 +/- 2,1 <b>Medication</b> 97,3 +/- 2,1 <b>Medication</b> 22 (31,4)         ACE-I/ARBs/ARNI/Aldosterone antagonis       21 (30)         Loop diuretic       6 (8,6)         ACE-I/ARBs/ARNI/Aldosterone antagonis       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Mins node dysfunction       27 (38,6)         Atrioventricular block       8 (11,4)         Ventricular arrhythmia       14 (20)         Supraventricular arrhythmia       31 (44,3)         BNP, ng/L       78,1+/-80,7	Age repair, month	7,3 +/- 5,4			
NYHA functional class       1,4 +/- 0,7         O2 saturation, %       97,3 +/- 2,1 <b>Medication</b> 22 (31,4)         Acte-I/ARBs/ARNI/Aldosterone antagonist       21 (30)         ACte-I/ARBs/ARNI/Aldosterone antagonist       21 (30)         Loop diuretic       6 (8,6)         Acte-I/ARBs/ARNI/Aldosterone antagonist       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Khythm history       27 (38,6)         Kutioventricular ablock       8 (11,4)         Loop diuretic       14 (20)         Bup and Loop diverticular armhythmias       14 (20)         Supraventricular armhythmias       31 (44,3)	Body Mass Index, kg.m-2	24,8 +/-5,5			
O2 saturation, %       97,3 +/- 2,1         Medication          Beta-blockers       22 (31,4)         ACE-I/ARBs/ARNI/Aldosterone antagonist       21 (30)         Loop diuretic       6 (86)         ACte-I/ARBs/ARNI/Aldosterone antagonist       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Pacemaker (Dual chamber or CRT)       15 (21,4)         Mutiarinduption       27 (38,6)         Khythm history       27 (38,6)         Kinioventricular anthythmis       8 (11,4)         Ventricular arthythmis       14 (20)         BNP, ng/L       58 (14,3)	NYHA functional class	1,4 +/- 0,7			
MedicationBeta-blockers $22$ (31,4)ACE-I/ARBs/ARNI/Aldosterone antagonia $21$ (30)Loop diureti $6$ (8,6)Antiarthythmic $13$ (18,6)Pacemaker (Dual chamber or CRT) $15$ (21,4)Pacemaker (Dual chamber or CRT) $15$ (21,4)Muthan bistory $27$ (38,6)Kniventricular block $8$ (11,4)Charticular arthythmia $14$ (20)Supraventricular arthythmia $31$ (44,3)BNF, ng/L $21$ (21,4)	O2 saturation, %	97,3 +/- 2,1			
Beta-blockers       22 (31,4)         ACE-I/ARBs/ARNI/Aldosterone antagonist       21 (30)         Loop diuretic       6 (8,6)         Antiarrhythmic       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4) <b>Rhythm history</b> 15 (21,4)         Atrioventricular block       8 (11,4)         Atrioventricular block       14 (20)         Supraventricular arrhythmia       31 (44,3)         BNP, ng/L       5 (21,4)	Medication				
ACE-I/ARBs/ARNI/Aldosterone antagonist       21 (30)         Loop diuretic       6 (8,6)         Antiarrhythmic       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4) <b>Rhythm history</b> 15 (21,4)         Antiarrhythmic       27 (38,6)         Atrioventricular block       8 (11,4)         Atrioventricular arrhythmias       14 (20)         BNP, ng/L       50 (14,3)	Beta-blockers	22 (31,4)			
Loop diuretic       6 (8,6)         Antiarrhythmic       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4) <b>Rhythm history</b> 15 (21,4)         Sinus node dysfunction       27 (38,6)         Atrioventricular block       8 (11,4)         Yentricular arrhythmia       14 (20)         Supraventricular arrhythmian       31 (44,3)         BNP, ng/L       28 (1-2,3)	ACE-I/ARBs/ARNI/Aldosterone antagonist	21 (30)			
Antiarrhythmic       13 (18,6)         Pacemaker (Dual chamber or CRT)       15 (21,4) <b>Rhythm history</b> 5         Sinus node dysfunction       27 (38,6)         Atrioventricular block       8 (11,4)         Ventricular arrhythmias       14 (20)         Supraventricular arrhythmias       31 (44,3)         BNP, ng/L       78,1 +/- 80,7	Loop diuretic	6 (8,6)			
Pacemaker (Dual chamber or CRT)       15 (21,4) <b>Rhythm history</b> -         Sinus node dysfunction       27 (38,6)         Atrioventricular block       8 (11,4)         Ventricular arrhythmias       14 (20)         Supraventricular arrhythmias       31 (44,3)         BNP, ng/L       78,1 ±/- 80,7	Antiarrhythmic	13 (18,6)			
Rhythm history       27 (38,6)         Sinus node dysfunction       27 (38,6)         Atrioventricular block       8 (11,4)         Ventricular arrhythmias       14 (20)         Supraventricular arrhythmias       31 (44,3)         BNP, ng/L       78,1 +/- 80,7	Pacemaker (Dual chamber or CRT)	15 (21,4)			
Sinus node dysfunction       27 (38,6)         Atrioventricular block       8 (11,4)         Ventricular arrhythmias       14 (20)         Supraventricular arrhythmias       31 (44,3)         BNP, ng/L       78,1 +/- 80,7	<u>Rhythm history</u>				
Atrioventricular block8 (11,4)Ventricular arrhythmias14 (20)Supraventricular arrhythmias31 (44,3)BNP, ng/L78,1 +/- 80,7	Sinus node dysfunction	27 (38,6)			
Ventricular arrhythmias14 (20)Supraventricular arrhythmias31 (44,3)BNP, ng/L78,1 +/- 80,7	Atrioventricular block	8 (11,4)			
Supraventricular arrhythmias31 (44,3)BNP, ng/L78,1 +/- 80,7	Ventricular arrhythmias	14 (20)			
BNP, ng/L 78,1 +/- 80,7	Supraventricular arrhythmias	31 (44,3)			
	BNP, ng/L	78,1 +/- 80,7			

Data are mean ± standard deviation or number (%) unless otherwise specified. ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor neprilysin inhibitor; BNP: B-type natriuretic peptide; NYHA: New York Heart Association; TGA: Transposition of Great Artery

# Table B: Resting imaging data

Echocardiography	N = 70
TAPSE, mm	12,5 +/- 3,4
S', cm/s	7,3 +/- 1,9
RV FAC, %	34,6 +/- 7,4
GLS RV, %	-11,9 +/- 2,9
SAVV Trivial-mild/moderate/severe	57 (81,4) / 10 (14,5) / 2 (2,9)
LVOTO	22 (31,4)

Cardiac Magnetic Resonance	N = 56
RV EF, %	49,1 +/- 9,8
RV EDV, mL/m <sup>2</sup>	107,1 +/-28,8
RV ESV, mL/m <sup>2</sup>	57,9 +/- 29,6
LV EF, %	59,4 +/- 7,9
LV EDV, mL/m <sup>2</sup>	64,6 +/- 17,5
LV ESV, mL/m <sup>2</sup>	26,9 +/- 10
Late Gadolinium Enhancement	10 (27)
Baffle leaks	4 (5,7)
Baffle stenosis	4 (5,7)

Data are mean ± standard deviation or number (%) unless otherwise specified. EDV: End-diastolic Volume; EF: Ejection Fraction; ESV: End-systolic Volume; FAC: Fractional area change; GLS: Global Longitudinal Strain; LV: Left Ventricle; LVOTO: Left Ventricular Outflow Trac Obstruction; RV: Right Ventricle; S': Tricuspid annular plane systolic velocity; SAVV: Systemic AtrioVentricular Valve; TAPSE: Tricuspid annular plane systolic excursion

	Lower tertile (N = 26)	Middle tertile (N = 22)	Upper tertile (N = 22)	p for Bo test or	onferroni / Fisher's ex	<i>post-hoc</i> kact test
				1 vs. 2	1 vs. 3	2 vs. 3
ppVO2%	43.4 +/- 9.2	57.2 +/- 3.4	72.7	<0.001	<0.001	<0.001
Age, years	32.9 +/-9	32.1 +/- 7	32 +/- 6.8	1.0000	1.0000	1.0000
Male gender	18 (69.2)	17 (77.3)	16 (72.7)	0.7460	1.0000	1.0000
TGA complex	8 (30.8)	5 (22.7)	6 (27.3)	0.7460	1.0000	1.0000
Age at repair, month	6.4 (5.2)	8.1 +/-5.4	7.5 +/-5.7	1.0000	1.0000	1.0000
NYHA functional class	1.8 +/- 0.8	1.4 +/- 0.6	1 +/- 0.2	0.0713	<0.001	0.2458
Antiarrhythmic therapy	8 (30.8)	3 (13.6)	2 (9.1)	0.1890	0.0840	1.0000
Beta-blocker	13 (50)	6 (27.3)	3 13.6)	0.1440	0.0130	0.4570
Pacemaker	9 (34.6)	4 (18.2)	2 (9.1)	0.3290	0.0450	0.6640
History of SND	12 (46.2)	7 (31.8)	8 (36.4)	0.3820	0.5650	1.0000
<u>Echocardiography</u>						
TAPSE, mm	12.5 +/- 3.6	12.2 +/- 2.6	12.6 +/- 4.1	1.0000	1.0000	1.0000
S', cm/s	6.78 +/- 1.8	7.5 +/- 1.7	7.7 +/- 2.1	0.5714	0.3275	1.0000
RV FAC, %	36.2 +/- 9	30.8 +/- 6	35.6 +/- 5.9	0.1603	1.0000	0.2254
Strain VD Global	-11.3 +/- 3.5	-12.8 +/- 2.7	-11.22 +/- 1.5	0.9001	1.0000	1.0000
CMR						
RV EF, %	48.2 +/- 10.9	48 +/- 8.7	51 +/- 10.1	1.0000	1.0000	1.0000
RV EDV (mL/m <sup>2</sup> )	102.9 +/- 34.8	112.8 +/- 28.2	105.5 +/- 23.4	0.9245	1.0000	1.0000
RV ESV (mL/m <sup>2</sup> )	55.1 +/- 28	64.6 +/- 38.9	53.8 +/- 18.8	1.0000	1.0000	0.8030

## Table C.1: Patient demographics and resting imaging data according to % ppVO2 tertiles

Data are expressed as mean ± standard deviation or n (%) unless specified otherwise. CMR: Cardiac Magnetic Resonance; EDV: End-diastolic Volume; EF: Ejection Fraction; ESV: Endsystolic Volume; FAC: Fractional area change; GLS: Global Longitudinal Strain; LV: Left Ventricle; NYHA: New York Heart Association; ppVO2 = peak VO2 of predicted VO2 %; RV: Right Ventricle; S': Tricuspid annular plane systolic velocity; SAVV: Systemic AtrioVentricular Valve; SND: Sinus Node Dysfunction; TAPSE: Tricuspid annular plain systolic excursion; TTE: Transthoracic Echocardiography

	Lower tertile (N = 26)	Middle tertile (N = 22)	Upper tertile (N = 22)	p for Bonferroni <i>post-hoc</i> test or Fisher's exact test		<i>post-hoc</i> xact test
				1 vs. 2	1 vs. 3	2 vs. 3
Sinus rhythm	18 (69.2)	16 (72.7)	15 (68.2)	0.4847	0.2823	0.2434
Peak power output, Watt	101.12 +/- 24.1	121.9 +/- 22.7	136.8 +/- 36.8	0.0459	<0.001	0.2700
Peak SBP, mm Hg	151.6 +/- 20	163.4 +/- 25.7	166.8 +/- 19.2	0.2033	0.0587	1.0000
Peak heart rate, bpm	134.4 +/- 29.2	150.3 +/- 19.6	164.4 +/- 19.5	0.0697	<0.001	0.1673
HRR, bpm	71.9 +/- 26.9	85.5 +/-19.8	99.3 +/- 21.8	0.1430	0.0003	0.1700
Age-adjusted HRR, %	57.7 +/- 20.7	69.5 +/- 13.4	80.7 +/- 14.6	0.0570	<0.001	0.0990
Chronotropic incompetence	20 (76.9)	17 (77.3)	8 (38.1)	1.0000	0.0160	0.0140
Peak VO2, mL/kg/min	17.1 +/- 4.5	22.1 +/- 4.2	26.1 +/- 4.7	<0.001	<0.001	0.0124
VE/VCO2 slope	39.3 +/- 7.5	37.5 +/- 7.5	34.1 +/- 9	1.0000	0.0933	0.5165
Peak Circulatory power,						
mmHg.mL.min-1.kg-2	2585.4 +/- 767.1	3687.5 +/- 939.4	4424.3 +/- 1182	<0.001	<0.001	0.0432
Peak O2 pulse, % of predicted	56.9 +/- 20.8	63.2 +/- 14.4	72.9 +/- 15.3	0.6853	0.0106	0.2323
Coefficient of increase O2						
pulse	2.11 +/- 0.6	2.24 +/- 0.6	3.07 +/- 1.16	1.0000	0.0010	0.0050
VAT, % of peak VO2	66.4 +/- 11.1	59 +/- 13.4	59.6 +/- 15	0.1797	0.2594	1.0000
VAT, % of ppVO2	29.2 +/- 7.5	35.1 +/- 7.1	42.9 +/- 12.7	0.1030	<0.001	0.0225
Pulmonary parameters						
FVC	74 +/- 17.7	79 +/- 8.9	83.9 +/- 12.3	0.6714	0.0512	0.7515
FEV1	80.1 +/- 16.9	80.6 +/- 9.6	82.4 +/- 12.9	1.0000	1.0000	1.0000
FEV1/FVC	106.1 +/- 8.3	105.4 +/- 7.5	101.7 +/- 10.9	1.0000	0.3367	0.6178
Respiratory Rate at peak	36.7 +/- 7.9	36.6 +/- 8.9	37.5 +/- 10.3	1.0000	1.0000	1.0000
VD/VT at rest	0.32 +/- 0.05	0.31 +/- 0.08	0.36 +/- 0.07	0.6728	0.3130	0.0209
VD/VT at peak	0.267 +/- 0.05	0.23 +/- 0.05	0.21 +/- 0.05	0.0693	0.0095	1.0000
Ventilatory Reserve at peak, %	42.4 +/- 11.1	30.2 +/- 13.5	24.4 +/- 17.1	0.0183	<0.001	0.5825

# Table C.2: CPET characteristics according to % ppVO2 tertiles

Data are expressed as mean ± standard deviation or n (%) unless specified otherwise.

FEV1: Forced expiratory volume in 1 second; FVC: Forced vital capacity; PetCO2: End-tidal CO2 tension; VCO2: Carbon dioxide output; VE: Minute ventilation; VO2: Oxygen uptake; VE/VCO2:

Ventilatory equivalent of carbon dioxide; VE/VO2: Ventilatory equivalent of oxygen; VAT: Ventilatory Anaerobic threshold; VD/VT: Volume of dead space / Tidal volume ratio

# Supplemental data

# Appendix: CPET data

	N = 70
Rhythm at CPET	
Heart rate at rest, bpm	63.9 +/- 12.7
Sinus rhythm	49 (70%)
Sinus node dysfunction	13 (18.6%)
Atrial paced rhythm	6 (8.6%)
CPET characteristics	
Peak power output, Watt	118.8 +/- 31.8
Peak SBP, mm Hg	160.2 +/- 22.4
RQ at peak VO2	1.2 +/- 0.1
Peak heart rate, bpm	148.6 +/- 26.2
Maximum heart rate, % Age predicted	78.9 +/- 12.4
HRR, bpm	84.6 +/- 25.4
Age-adjusted HRR, %	68.5 +/- 19.1
Chronotropic incompetence	46.0 (65.7)
Peak VO2, mL/kg/min	21.51 +/- 5.81
Peak VO2, % of predicted peak VO2	56.95 +/- 14.13
Peak VO2, L/min	1.511 +/- 0.512
VE/VCO2 slope	37.1 +/- 8.2
Circulatory power, mmHg.mL.min-1.kg-2	3536.9 +/- 1227.5
Oxygen pulse at rest, mL/beat	4.5 +/- 1.4
Peak oxygen pulse, mL/beat	10.4 +/- 3.6
Peak oxygen pulse, % of predicted	63.9 +/- 18.2
Coefficient of increase O2 pulse	2.46 +/- 0.9
VAT, min	5.1 +/- 2
VAT, mL/kg/min	13.4 +/- 3.9
VAT, % of peak VO2	61.8 +/- 13.4
VAT, % of predicted peak VO2	35.4 +/- 10.8

Data are expressed as mean  $\pm$  standard deviation or n (%) unless specified otherwise.

<b>Pulmonary parameters</b>	N = 70
FVC	78.6 +/- 14.2
FEV1	81.0 +/- 13.6
FEV1/FVC	104.4 +/- 9.1
Respiratory Rate at rest	17.2 +/- 5.6
Respiratory Rate at peak Vo2	36.9 +/- 8.9
PetCO2 at rest, mmHg	31.0 +/- 3.7
PetCO2 at VAT, mmHg	36.5 +/- 4.9
PetCo2 at peak VO2, mmHg	30.1 +/- 4.6
VE/VCO2 at VAT	34.4 +/- 5.5
VE/VO2 at VAT	32.3 +/- 6.9
VE/VO2 at peak VO2	48.3 +/- 11.3
VD/VT at rest	0.33 +/- 0.07
VD/VT at peak	0.24 +/- 0.06
VE at rest, L/min	11.9 +/- 3
VE at peak VO2, L/min	70.2 +/- 18.4
Ventilatory reserve at rest, %	87.8 +/- 5.8
Ventilatory reserve at peak VO2, %	33.0 +/- 15.8

HRR: Heart Rate Reserve; RQ: Respiratory Quotient; SBP: Systolic Blood Pressure; VAT; Ventilatory Anaerobic Threefold; VE/VCO2: Ventilatory equivalent of carbon dioxide; VO2: Oxygen uptake

Data are expressed as mean ± standard deviation or n (%) unless specified otherwise. FEV1: Forced expiratory volume in 1 second; FVC: Forced vital capacity; PetCO2: End-tidal CO2 tension; VCO2: Carbon dioxide output; VE: Minute ventilation; VO2: Oxygen uptake; VE/VCO2: Ventilatory equivalent of carbon dioxide; VE/VO2: Ventilatory equivalent of oxygen; VAT: Ventilatory Anaerobic threshold; VD/VT: Volume of dead space / Tidal volume ratio